Millennium Management
PTGX icon

Millennium Management’s Protagonist Therapeutics PTGX Stock Holding History

Millennium Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$546K – 6754
2022
Q4 		$546K Buy
+50,000
New +$422K ﹤0.01% 4682
2022
Q1 		– Sell
-20,000
Closed -$684K – 7369
2021
Q4 		$684K Buy
+20,000
New +$632K ﹤0.01% 4765

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Millennium Management's PTGX Position: Q1 2026 in Review

Millennium Management sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 17,391 shares — an estimated $1.52M sold.

Millennium Management first reported a position in PTGX in Q2 2017 and held it in 31 quarters. The position peaked at $33.2M in Q2 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Millennium Management reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 17,391 Protagonist Therapeutics shares in Q1 2026, an estimated $1.52M.
  • Millennium Management first reported a position in Protagonist Therapeutics in Q2 2017 and held it in 31 quarters.
  • Millennium Management's Protagonist Therapeutics position peaked at $33.2M in Q2 2024.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.